Zoetis (ZTS) Capital Expenditures (2012 - 2026)
Zoetis (ZTS) posted quarterly Capital Expenditures of $110.0 million for Q1 2026, down 38.2% year-over-year from $178.0 million in Q1 2025, and down 82.2% quarter-over-quarter from $618.0 million in Q4 2025.
Zoetis (ZTS) Capital Expenditures (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Capital Expenditures for 15 consecutive years, with $110.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 38.2% year-over-year to $110.0 million; the TTM figure through Mar 2026 stood at $553.0 million (up 1248.78% YoY), while the FY2025 annual figure was $621.0 million, up 20600.0% from the prior year.
- Capital Expenditures fell to $110.0 million in Q1 2026 per ZTS's latest filing, from $618.0 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $618.0 million in Q4 2025 and bottomed at -$385.0 million in Q3 2023.
- Historically, Capital Expenditures has averaged $82.6 million across 5 years, with a median of $3.5 million in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 61900.0% in 2025 and fell as far as 32500.0% in 2025.
- Zoetis' Capital Expenditures stood at $581.0 million in 2022, then sank by 100.34% to -$2.0 million in 2023, then jumped by 50.0% to -$1.0 million in 2024, then jumped by 61900.0% to $618.0 million in 2025, then plunged by 82.2% to $110.0 million in 2026.
- Business Quant data shows ZTS's Capital Expenditures at $110.0 million in Q1 2026, $618.0 million in Q4 2025, and -$324.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 8.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 117.00 Mn |
| Jun 30, 2026 | 117.00 Mn |
| Mar 31, 2026 | 110.00 Mn |
| Mar 31, 2026 | 110.00 Mn |
| Dec 31, 2025 | 618.00 Mn |
| Dec 31, 2025 | 618.00 Mn |
| Sep 30, 2025 | -324.00 Mn |
| Sep 30, 2025 | -324.00 Mn |
| Jun 30, 2025 | 149.00 Mn |
| Jun 30, 2025 | 149.00 Mn |
| Mar 31, 2025 | 178.00 Mn |
| Mar 31, 2025 | 178.00 Mn |
| Dec 31, 2024 | -1.00 Mn |
| Dec 31, 2024 | -1.00 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | -137.00 Mn |
| Jun 30, 2024 | -137.00 Mn |
| Mar 31, 2024 | 140.00 Mn |
| Mar 31, 2024 | 140.00 Mn |